Management of Locoregionally Advanced Melanoma

David T Pointer Jr; Jonathan S Zager

doi:10.1016/j.suc.2019.09.003

Management of Locoregionally Advanced Melanoma

Surg Clin North Am. 2020 Feb;100(1):109-125. doi: 10.1016/j.suc.2019.09.003. Epub 2019 Oct 28.

Authors

David T Pointer Jr¹, Jonathan S Zager²

Affiliations

¹ Department of Cutaneous Oncology, Moffitt Cancer Center, 10920 McKinley Drive, Tampa, FL, 33612; Department of Surgery, University of South Florida Morsani College of Medicine, 13220 USF Laurel Dr., Tampa, FL 33612.
² Department of Cutaneous Oncology, Moffitt Cancer Center, 10920 McKinley Drive, Tampa, FL, 33612; Department of Surgery, University of South Florida Morsani College of Medicine, 13220 USF Laurel Dr., Tampa, FL 33612. Electronic address: [email protected].

PMID: 31753106
DOI: 10.1016/j.suc.2019.09.003

Abstract

Melanoma has a unique propensity for locoregional metastasis secondary to intralymphatic transit not seen in other cutaneous or soft tissue malignancies. Novel intralesional therapies using oncolytic immunotherapy exhibit increasing response rates with observed bystander effect. Intralesional modalities in combination with systemic immunotherapy are the subject of ongoing clinical trials. Regional therapy is used in isolated limb locoregional metastasis whereby chemotherapy is delivered to an isolated limb avoiding systemic side effects. Multimodal treatment strategy is imperative in the treatment of locoregionally advanced melanoma. One must be versed on these quickly evolving therapeutic options.

Keywords: In-transit recurrence; Intralesional therapy; Locoregional metastasis; Melanoma; Metastatic melanoma; Oncolytic therapy; Satellite recurrence; T-VEC.

Publication types

Review

MeSH terms

Clinical Trials as Topic
Humans
Melanoma / pathology
Melanoma / therapy*
Skin Neoplasms / pathology
Skin Neoplasms / therapy*